Title: To Study the Medicine Use Evaluation in Stroke Patients in Hospital

Authors: Tyagi Shubham Singh, Singh Juhi, Jain Pankhuri, Tousib Mohd.

 DOI: https://dx.doi.org/10.18535/jmscr/v7i8.98

Abstract

Stroke is a big problem of mortality worldwide and commonly occurs in old patients. First prevention of stroke should include antiplatelet therapy with aspirin, statin therapy and blood pressure management. The current Observational prospective study of six months duration was performed to consider the sign ,symptoms and risk factors, prescribing pattern , appropriateness of medication, Drug related problems occur  in the stroke patients in neurology multispecialty healthcare setting of India. Ischemic stroke (78.57%) was more prevalent in our study, hyperlipidemia (47.05%) and hypertension (28.05%) were the most predominant diagnoses observed in majority of population. In our study majorly patients 19(27.14%) suffer from stroke was in 41-50 years age group male gender (79%) was more prone to stroke attacks, that too within age group of 51-60 years ,headache was more common symptom in stroke patients 57(12.6%),majority no. of symptoms 123(27.4%) was the cofound contributing risk factor. Anti-atherogenics and statins were commonly utilized in study population found rationale which is the value addition in stroke management. Drug related problems was assessed in 52 patients majorly identified drug related problem were drug interaction 37(69.8%), followed by medication error 13(24.52%), overdose 2(3.77%), sub therapeutic dose 1(1.8%).

References

  1. WHO MONICA Project Investigators. The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease). J Clin Epidemiol. 1988; (41): 105-114.
  2. Sims NR, Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochimica Et Biophysica Acta. 2009; 1802 (1): 80 -91.
  3. Adams HP Jr, Birgitte H, Bendixen BH, Kappelle LJ, J Biller, et al. Classification of subtype of acute ischemic stroke. Definitions for used in a multicenter clinical trial. TOAST. Trial of Org10172 in Acute Stroke Treatment. Stroke. 1993; 24 (1):35-41.
  4. Feigin VL. Stroke in developing countries: can the epidemic be stopped and outcomes improved? Lancet Neurology. 2007; 6 (2): 94–97.
  5. Smith SD, Eskey CJ. Hemorrhagic stroke. Radiol Clin North Am. 2011; 49: 27-45.
  6. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, et al. Risk factors. Stroke. 1997;28:1507-1517.
  7. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, et al. Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376 (9735): 112-123.
  8. Hewer RL, Tennant A. The epidemiology of disabling neurological disorders. Handbook of neurological rehabilitation. Edited by Greenwood RJ, Barnes MP, McMillan TM, Ward CD. Psychology Press. 2003: 5-14.
  9. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: Time window for prevention is very short. Neurology.2005; 64:817-820.
  10. Caplan, LR, van Gijn J, eds. Stroke Syndromes, 3rd ed. Cambridge: Cambridge University Press,2012.
  11. Heros R. Stroke: Early patho-physiology and treatment. Stroke.1994; 25:1877-1878.
  12. Department of Health and Human Services. The National Institute of Neurological Disorders and Stroke (NINDS). NIH Stroke Scale Training, Part 2. Basic Instruction. 2010.
  13. Ver Hage A. The NIH stroke scale: a window into neurological status. Nurse.Com; Nursing Spectrum (Greater Chicago). 2011; 24 (15):44-49.
  14. Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke.1996; 27:415-420.
  15. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study. Lancet, 2010; 380: 2095-128.
  16. Muhit MA, Rahman MO, Raihan SZ, Asaduzzaman M, Akbar MA, Sharmin N, et al. Cardiovascular disease prevalence and prescription patterns at a tertiary level hospital in Bangladesh. J Appl Pharm Sci., 2012; 2: 80-4.
  17. Manjula Devi AS, Sriram S, Rajalingam B, Alfet Raju A, Varghese RS, VenkataPhani A. Evaluation of the rationality of fixed dose combinations of cardiovascular drugs in a multispecialty tertiary care hospital in Coimbatore, Tamil Nadu, India. Hygeia: J Drugs Med., 2012; 4: 51-8.
  18. Khonputsa P, Veerman LJ, Bertram M, Lim SS, Chaiyakunnaphruk N, Vos T. Generalized cost-effectiveness analysis of pharmaceutical interventions for primary prevention of cardiovascular disease in Thailand. The values in Health Regional Issues, 2012; 1: 15-22.

Corresponding Author

Tyagi Shubham Singh

Research Scholar, Department of Pharmacy Practice Teerthanker Mahaveer University, College of Pharmacy Moradabad, NH24 Uttar Pradesh, India